Axoltis closed an $18 million Series A to advance NX210c, a cyclic peptide derived from an embryonic neuronal protein, through clinical development for amyotrophic lateral sclerosis (ALS). The financing included regional funds and the company’s CEO, Yann Godfrin, and will support the ongoing Phase II study (NCT06365216) that is evaluating efficacy, tolerability and the drug’s potential to repair the blood‑brain barrier (BBB). Axoltis said Phase Ib biomarker signals suggested NX210c repairs BBB integrity in elderly participants and announced Phase II readouts are expected in Q2 2026. Management plans to use the data to pursue partnership talks with large pharma to accelerate global development and access.